FDA-approved generic pergolide gives equine PPID care a new option
A newly approved generic pergolide product is giving equine veterinarians another option for managing pituitary pars intermedia dysfunction in horses. On January 9, 2026, the FDA said it approved Zygolide for control of clinical signs associated with PPID, also called equine Cushing’s disease, making it the first generic pergolide tablet approved for horses in the U.S. The product is sponsored by Dechra Veterinary Products and is bioequivalent to Prascend, the long-standing brand-name pergolide product in this category. (fda.gov)
That matters because PPID is a chronic endocrine disorder seen commonly in older horses, and pergolide has been the backbone of medical management for years. Prascend was first approved in 2011, and since then pergolide has remained the standard labeled therapy for controlling PPID clinical signs. The arrival of a generic does not change the underlying treatment approach, but it does introduce competition into a category where long-term medication cost and daily administration can shape whether horses stay consistently treated. (fda.gov)
FDA’s freedom of information summary shows Zygolide was approved under ANADA 200-823, with approval dated December 19, 2025. The agency said the sponsor demonstrated bioequivalence to 1 mg Prascend tablets in a crossover blood-level study in 24 healthy horses, and no serious adverse events were reported during that study. The labeled regimen mirrors established pergolide use: oral administration at a starting dose of 2 mcg/kg once daily, titrated to effect, with a maximum of 4 mcg/kg daily. Tablets are supplied as 1 mg prescription tablets in 60-count and 160-count cartons. (animaldrugsatfda.fda.gov)
Dechra’s positioning focuses on day-to-day use. In company materials and related promotional content, Zygolide is described as peppermint flavored and 360-degree, half-scored for dose flexibility and more consistent administration. That messaging appears aimed squarely at one of pergolide’s longstanding real-world challenges: some horses resist daily tablets, and dosing often needs fine adjustment over time based on clinical response and endocrine testing. The label also includes the same kinds of safety reminders equine teams already know from pergolide handling, including not crushing tablets and taking care to reduce human exposure when tablets are split. (dechra-us.com)
Direct independent expert reaction to Zygolide itself is still limited, but industry messaging is already framing the approval around affordability and adherence. Dechra has said the generic could offer cost relief, particularly for horses needing higher daily doses. Some veterinary practices and equine-facing outlets have echoed that point while highlighting the flavored, scored-tablet design as a practical administration benefit. That’s consistent with broader PPID management guidance, where success often depends not just on prescribing pergolide, but on keeping horses on therapy long enough to titrate dose and monitor ACTH or other endocrine markers over time. (biospace.com)
Why it matters: For veterinary professionals, Zygolide’s importance is operational. A bioequivalent generic may help reduce cost barriers for pet parents, improve willingness to start or continue treatment, and give clinicians another labeled option when adherence is shaky. In equine practice, where PPID often overlaps with laminitis risk, muscle loss, coat changes, and other chronic management issues, even modest gains in medication consistency can have outsized clinical value. The caveat is that a new generic does not eliminate the need for careful monitoring, dose titration, and staff education about safe handling. (fda.gov)
What to watch: The next signal will be uptake: whether veterinarians, pharmacies, and pet parents embrace Zygolide quickly enough to pressure pricing in the pergolide market, and whether Dechra’s palatability and scoring claims translate into measurable adherence advantages in real-world PPID care. (equinefacilitydesign.com)